Condition: Renal Cell Carcinoma · Kidney Cancer · Kidney Neoplasm · Sponsor: Dana-Farber Cancer Institute
The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)
This description comes directly from the study's public registry record.
Wenxin Xu, MD · 617-632-6534 · Wenxin_Xu1@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07397611